Safety and Tolerability of Antiretrovirals during Pregnancy
| Autor: | Jill K. Davies, Jeri Forster-Harwood, Carol Salbenblatt, Elizabeth Soda, Emily Barr, Kay Kinzie, Adriana Weinberg, Suzanne Paul, Anna Vazquez, Myron J. Levin, Elizabeth J. McFarland, Jennifer Pappas |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2011 |
| Předmět: |
Adult
Pediatrics medicine.medical_specialty Nevirapine Article Subject HIV Infections Dermatology Pharmacology lcsh:Gynecology and obstetrics lcsh:Infectious and parasitic diseases Zidovudine Indinavir Pregnancy Risk Factors immune system diseases medicine Humans lcsh:RC109-216 Pregnancy Complications Infectious lcsh:RG1-991 Retrospective Studies business.industry Stavudine Obstetrics and Gynecology virus diseases Lopinavir biochemical phenomena metabolism and nutrition Infectious Disease Transmission Vertical Infectious Diseases Nelfinavir Tolerability Anti-Retroviral Agents Clinical Study Ritonavir Drug Therapy Combination Female business medicine.drug |
| Zdroj: | Infectious Diseases in Obstetrics and Gynecology, Vol 2011 (2011) Infectious Diseases in Obstetrics and Gynecology |
| ISSN: | 1098-0997 1064-7449 |
| Popis: | Combination antiretroviral therapy (CART) dramatically decreases mother-to-child HIV-1 transmission (MTCT), but maternal adverse events are not infrequent. A review of 117 locally followed pregnancies revealed 7 grade ≥3 AEs possibly related to antiretrovirals, including 2 hematologic, 3 hepatic, and 2 obstetric cholestasis cases. A fetal demise was attributed to obstetric cholestasis, but no maternal deaths occurred. The drugs possibly associated with these AE were zidovudine, nelfinavir, lopinavir/ritonavir, and indinavir. AE or intolerability required discontinuation/substitution of nevirapine in 16% of the users, zidovudine in 10%, nelfinavir in 9%, lopinavir/ritonavir in 1%, but epivir and stavudine in none. In conclusion, nevirapine, zidovudine, and nelfinavir had the highest frequency of AE and/or the lowest tolerability during pregnancy. Although nevirapine and nelfinavir are infrequently used in pregnancy at present, zidovudine is included in most MTCT preventative regimens. Our data emphasize the need to revise the treatment recommendations for pregnant women to include safer and better-tolerated drugs. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|